These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 20197469)

  • 1. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.
    Hashizume H; Falcón BL; Kuroda T; Baluk P; Coxon A; Yu D; Bready JV; Oliner JD; McDonald DM
    Cancer Res; 2010 Mar; 70(6):2213-23. PubMed ID: 20197469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours.
    Coutelle O; Schiffmann LM; Liwschitz M; Brunold M; Goede V; Hallek M; Kashkar H; Hacker UT
    Br J Cancer; 2015 Feb; 112(3):495-503. PubMed ID: 25562438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo.
    Suzuki R; Yamamoto H; Ngan CY; Ohtsuka M; Kitani K; Uemura M; Nishimura J; Takemasa I; Mizushima T; Sekimoto M; Minamoto T; Doki Y; Mori M
    Int J Oncol; 2013 Nov; 43(5):1447-55. PubMed ID: 23982687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.
    Falcón BL; Hashizume H; Koumoutsakos P; Chou J; Bready JV; Coxon A; Oliner JD; McDonald DM
    Am J Pathol; 2009 Nov; 175(5):2159-70. PubMed ID: 19815705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiopoietin-2 inhibition using siRNA or the peptide antagonist L1-10 results in antitumor activity in human neuroblastoma.
    D'Souza SS; Scherzinger-Laude K; Simon M; Salimath BP; Rössler J
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2017-26. PubMed ID: 22777681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
    Oliner J; Min H; Leal J; Yu D; Rao S; You E; Tang X; Kim H; Meyer S; Han SJ; Hawkins N; Rosenfeld R; Davy E; Graham K; Jacobsen F; Stevenson S; Ho J; Chen Q; Hartmann T; Michaels M; Kelley M; Li L; Sitney K; Martin F; Sun JR; Zhang N; Lu J; Estrada J; Kumar R; Coxon A; Kaufman S; Pretorius J; Scully S; Cattley R; Payton M; Coats S; Nguyen L; Desilva B; Ndifor A; Hayward I; Radinsky R; Boone T; Kendall R
    Cancer Cell; 2004 Nov; 6(5):507-16. PubMed ID: 15542434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
    Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
    Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.
    Huang H; Lai JY; Do J; Liu D; Li L; Del Rosario J; Doppalapudi VR; Pirie-Shepherd S; Levin N; Bradshaw C; Woodnutt G; Lappe R; Bhat A
    Clin Cancer Res; 2011 Mar; 17(5):1001-11. PubMed ID: 21233403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.
    Brown JL; Cao ZA; Pinzon-Ortiz M; Kendrew J; Reimer C; Wen S; Zhou JQ; Tabrizi M; Emery S; McDermott B; Pablo L; McCoon P; Bedian V; Blakey DC
    Mol Cancer Ther; 2010 Jan; 9(1):145-56. PubMed ID: 20053776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking Angiopoietin-2 Promotes Vascular Damage and Growth Inhibition in Mouse Tumors Treated with Small Doses of Radiation.
    Kallio P; Jokinen E; Högström J; Das S; Heino S; Lähde M; Brodkin J; Korhonen EA; Alitalo K
    Cancer Res; 2020 Jun; 80(12):2639-2650. PubMed ID: 32312835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition.
    Hofmann I; Baum A; Hofmann MH; Trapani F; Reichel-Voda C; Ehrensperger D; Aichinger M; Ebner F; Budano N; Schweifer N; Sykora M; Depla E; Boucneau J; Gschwind A; Kraut N; Hilberg F; Künkele KP
    J Pharmacol Exp Ther; 2023 Mar; 384(3):331-342. PubMed ID: 36241203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
    Lin YC; Liu CY; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.
    Coxon A; Bready J; Min H; Kaufman S; Leal J; Yu D; Lee TA; Sun JR; Estrada J; Bolon B; McCabe J; Wang L; Rex K; Caenepeel S; Hughes P; Cordover D; Kim H; Han SJ; Michaels ML; Hsu E; Shimamoto G; Cattley R; Hurh E; Nguyen L; Wang SX; Ndifor A; Hayward IJ; Falcón BL; McDonald DM; Li L; Boone T; Kendall R; Radinsky R; Oliner JD
    Mol Cancer Ther; 2010 Oct; 9(10):2641-51. PubMed ID: 20937592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.
    Sarraf-Yazdi S; Mi J; Moeller BJ; Niu X; White RR; Kontos CD; Sullenger BA; Dewhirst MW; Clary BM
    J Surg Res; 2008 May; 146(1):16-23. PubMed ID: 17950331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth.
    Cao Y; Sonveaux P; Liu S; Zhao Y; Mi J; Clary BM; Li CY; Kontos CD; Dewhirst MW
    Cancer Res; 2007 Apr; 67(8):3835-44. PubMed ID: 17440098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis.
    Holopainen T; Saharinen P; D'Amico G; Lampinen A; Eklund L; Sormunen R; Anisimov A; Zarkada G; Lohela M; Heloterä H; Tammela T; Benjamin LE; Ylä-Herttuala S; Leow CC; Koh GY; Alitalo K
    J Natl Cancer Inst; 2012 Mar; 104(6):461-75. PubMed ID: 22343031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor inhibitors in colon cancer.
    Díaz-Rubio E
    Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis.
    Rennel ES; Regula JT; Harper SJ; Thomas M; Klein C; Bates DO
    Microcirculation; 2011 Oct; 18(7):598-607. PubMed ID: 21851472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.